Education
About Us
Working with TipRanks
Follow Us
CytomX Therapeutics Inc. (CTMX)
:CTMX
CTMX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.40 - $3.10
Previous CloseN/A
Volume1.08M
Average Volume (3M)3.49M
Market Cap
$318.28M
Enterprise Value$141.80M
Total Cash (Recent Filing)$79.89M
Total Debt (Recent Filing)$8.15M
Price to Earnings (P/E)3.4
Beta2.96
Next Earnings
Nov 06, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding164,912,900
10 Day Avg. Volume2,642,826
30 Day Avg. Volume3,490,407
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue0.96
Enterprise Value/Gross Profit0.96
Enterprise Value/Ebitda3.77
Forecast
1Y Price Target
$4.79Price Target Upside148.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsCX-2051 achieved a 28% confirmed ORR across the expansion dose levels, with an impressive 43% confirmed ORR at 10mg/kg and sufficient durability with 5.8 months mPFS.
Financial PerformanceCTMX reported no net loss or $0/share, above the estimate of ($0.14).
Regulatory ProgressThe trial has continued to enroll without interruption, which implies that the FDA has acknowledged the event and not placed the program under any form of clinical hold.
Bears Say
Stock PerformanceThe market has already reacted to the development, with shares of CytomX down ~20% since the day prior to the press release.
CytomX Therapeutics News
CTMX FAQ
What was CytomX Therapeutics Inc.’s price range in the past 12 months?
CytomX Therapeutics Inc. lowest stock price was $0.40 and its highest was $3.10 in the past 12 months.
What is CytomX Therapeutics Inc.’s market cap?
CytomX Therapeutics Inc.’s market cap is $318.28M.
When is CytomX Therapeutics Inc.’s upcoming earnings report date?
CytomX Therapeutics Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 49 days.
How were CytomX Therapeutics Inc.’s earnings last quarter?
CytomX Therapeutics Inc. released its earnings results on Aug 07, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.063 by $0.063.
Is CytomX Therapeutics Inc. overvalued?
According to Wall Street analysts CytomX Therapeutics Inc.’s price is currently Undervalued.
Does CytomX Therapeutics Inc. pay dividends?
CytomX Therapeutics Inc. does not currently pay dividends.
What is CytomX Therapeutics Inc.’s EPS estimate?
CytomX Therapeutics Inc.’s EPS estimate is -0.05.
How many shares outstanding does CytomX Therapeutics Inc. have?
CytomX Therapeutics Inc. has 164,912,900 shares outstanding.
What happened to CytomX Therapeutics Inc.’s price movement after its last earnings report?
CytomX Therapeutics Inc. reported an EPS of $0 in its last earnings report, beating expectations of -$0.063. Following the earnings report the stock price went up 11.905%.
Which hedge fund is a major shareholder of CytomX Therapeutics Inc.?
Currently, no hedge funds are holding shares in CTMX
CytomX Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.79 (148.19% Upside)
$4.79 (148.19% Upside)
Blogger Sentiment
Bullish
CTMX Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 16.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.9%
Last 30 Days ▲ 23.2%
Last 30 Days ▲ 23.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.50%
12-Months-Change
Fundamentals
Return on Equity
108.21%
Trailing 12-Months
Asset Growth
9.95%
Trailing 12-Months
Company Description
CytomX Therapeutics Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
CTMX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical progress, particularly with CX-2051, and strong financial positioning, although there were challenges with decreased revenue and common adverse events in clinical trials.View all CTMX earnings summariesCTMX Stock 12 Month Forecast
Average Price Target
$4.79
▲(148.19% Upside)
Technical Analysis
PDS Biotechnology
―
Cue Biopharma
―
Acrivon Therapeutics, Inc.
―
Fractyl Health, Inc.
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
1.18% Insiders
6.17% Mutual Funds
50.23% Other Institutional Investors
37.71% Public Companies and
Individual Investors